Evidence map›Paper›PMID 29611176›Full record

Trial reportBritish journal of haematology2019

The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.

Rebecca Citrin, Kelly D Getz, Yimei Li, Yuan-Shung Huang, Joseph P Horowitz, Alix E Seif, Brian T Fisher, Richard Aplenc

Abstract readClinical TrialLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca CitrinDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-5651-0523
Kelly D GetzDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Yimei LiDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Yuan-Shung HuangCenter for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Joseph P HorowitzDrexel University College of Medicine, Philadelphia, PA, USA.
Alix E SeifDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Brian T FisherCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Richard AplencDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Genetic Predictors of AML Treatment ResponseR01CA133881 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI APLENC, RICHARD · 2010 to 2014
$2.8M
NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA133881
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultChildChild, PreschoolHumansInfantLymphoma, Non-HodgkinMalePrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesUrate OxidaserasburicaseUrate Oxidasehyperuricaemianon-Hodgkin lymphoma, acute leukaemiarasburicasetumour lysis syndrome.

Identifiers

PMID29611176
PMCPMC6168433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.